Dolores Catania, ‘Traitors’ Star, Makes Bold Admission About Her Ozempic Use
Between being a cast member on The Real Housewives of New Jersey, starring in the latest season of the hit competition show ...
Superbowl Ad Sparks A Healthy Controversy About Medication Safety
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Ozempic competitors show there’s much to gain in weight loss drugs
Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.
Modern Healthcare2d
Ozempic, Wegovy maker responds to Hims & Hers Super Bowl ad
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
Novo Nordisk: 2024 Earnings Review
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Newsable Asianet News on MSN5d
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Search Engine Land7d
Dominate your competition
Discover your competitors’ top keywords, backlinks, and traffic sources instantly. Simply enter a domain to begin. Chat with SearchBot Please note that your conversations will be recorded.
Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...
Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns.
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.
Novo Nordisk Expects Slowing Sales Growth This Year — Update
Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...